Skip to content
Screener

Net Income at other companies

Amgen logo
AmgenAMGN
$2.38B+65.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.3B-6.8%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
-$8.86M-220%
Regenxbio logo
RegenxbioRGNX
$22.71M+132%
Immunome logo
ImmunomeIMNM
-$53.84M-29.3%
CG Oncology logo
CG OncologyCGON
-$79.06M-90.8%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+160%
Enterprise value$967.91M+162%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026.

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805
Line itemThree Months Ended December 31, 2025Three Months Ended December 31, 2024Nine Months Ended December 31, 2025Nine Months Ended December 31, 2024
Interest expense on debt obligations(1,466)(1,450)(4,429)(4,314)
Other (expense) income, net(580)(3,281)(865)(850)
Total other income (expense), net6272545,5479,707
Loss before income taxes$(71,241)$(65,765)$(241,034)$(172,592)
Income tax (benefit) provision(311)$575$(311)$575
Net loss$(70,930)$(66,340)$(240,723)$(173,167)
Net loss per common share, basic and diluted$(0.77)$(0.79)$(2.62)$(2.25)
Weighted average common shares outstanding, basic and diluted92,187,58183,498,89291,874,48177,113,695

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Replimune Group's net income?
Replimune Group (REPL) reported net income of -$70.93M in Q4 2025.
How has Replimune Group's net income changed year-over-year?
Replimune Group's net income decreased by 6.9% year-over-year, from -$66.34M to -$70.93M.
What is the long-term trend for Replimune Group's net income?
Over 3 years (2022 to 2025), Replimune Group's net income has grown at a 28.0% compound annual growth rate (CAGR), from -$118.04M to -$247.3M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Replimune Group's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude